Drug and Alcohol Rehabilitation: Community Capacity Assessment in Preventing Substance Abuse: A Participatory Approach.

Community capacity assessment in preventing substance abuse: a participatory approach.

Filed under: Drug and Alcohol Rehabilitation

Iran J Public Health. 2012; 41(9): 48-55
Shahandeh Kh, Majdzadeh R, Jamshidi E, Loori N

Community-based participatory research (CBPR) increasingly is being used to address health issues. Few evidence exist to indicate how builds the capacity of communities to function as health promoter and what resources are required to promote successful efforts. This article presents the result of a capacity assessment for preventing drug abuse through CBPR, which working with rather than in communities, to strengthen a community’s problem-solving capacity. For exploring the perception of stakeholders, a dynamic model of the dimensions of community and partnership capacity served as the theoretical framework.In this descriptive research, stakeholder analysis helps us to identify appropriate of stakeholders (Key stakeholders). Data were collected using a topic guide concerned with capacity for preventing drug abuse. Interviews were audiotape and transcribed. Data were analyzed thematically.CBPR has been undertaken to involve local people in making decisions about the kind of change they want in their community and the allocation of resources to reduce substance abuse. We identified key stakeholders and examining their interests, resources and constraints of different stakeholders.The current study has shown the benefits of community-based participatory approach in assessing capacity. Through CBPR process people who affected by Drug issue engaged in analysis of their own situation and helps identity innovative solutions for their complex problem. This participatory approach to a capacity assessment resulted in a synergistic effort that provided a more accurate picture of community issues and concerns.
HubMed – drug

Pharmacists’ Research Contributions in the Fight against HIV/AIDs.

Filed under: Drug and Alcohol Rehabilitation

AIDS Res Treat. 2012; 2012: 869891
Horace AE

Pharmacists have made many contributions to HIV/AIDs research and are still showing their significance as members of the healthcare team through innovative clinical trials. Pharmacists are showing advances in several healthcare settings including inpatient, outpatient, and community pharmacies. Because of the complex regimens of highly active antiretroviral therapy (HAART), the increased life span of patients living with HIV, and other concomitant medications taken for comorbid disease states, there is a high risk for health-related complications and the development of adverse events. These adverse events may lead to decreased adherence to HAART, which may cause the development of HIV drug resistance. Pharmacists are providing examples through growing research on how they help combat medication-related errors and also continue to contribute as healthcare providers as a part of a holistic healthcare team.
HubMed – drug

Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future.

Filed under: Drug and Alcohol Rehabilitation

AIDS Res Treat. 2012; 2012: 595762
Harris M, Nosyk B, Harrigan R, Lima VD, Cohen C, Montaner J

In the early years of the highly active antiretroviral therapy (HAART) era, HIV with resistance to two or more agents in different antiretroviral classes posed a significant clinical challenge. Multidrug-resistant (MDR) HIV was an important cause of treatment failure, morbidity, and mortality. Treatment options at the time were limited; multiple drug regimens with or without enfuvirtide were used with some success but proved to be difficult to sustain for reasons of tolerability, toxicity, and cost. Starting in 2006, data began to emerge supporting the use of new drugs from the original antiretroviral classes (tipranavir, darunavir, and etravirine) and drugs from new classes (raltegravir and maraviroc) for the treatment of MDR HIV. Their availability has enabled patients with MDR HIV to achieve full and durable viral suppression with more compact and cost-effective regimens including at least two and often three fully active agents. The emergence of drug-resistant HIV is expected to continue to become less frequent in the future, driven by improvements in the convenience, tolerability, efficacy, and durability of first-line HAART regimens. To continue this trend, the optimal rollout of HAART in both rich and resource-limited settings will require careful planning and strategic use of antiretroviral drugs and monitoring technologies.
HubMed – drug

More Drug And Alcohol Rehabilitation Information…